Millennium Pharmaceuticals has agreed to acquire Cambridge Discovery Chemistry, a wholly-owned subsidiary of the UK’s Oxford Molecular Group, for $53 million in cash.
To finance the deal, Millennium said it would sell securities in a private placement.
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
